February 9, 2020 / 9:37 PM / 17 days ago

BRIEF-Oxurion Announces Positive Topline Data From Phase 1 Study Evaluating Thr-687 For Treatment Of DME

Feb 9 (Reuters) - Oxurion NV:

* OXURION- PRESENTATION OF POSITIVE TOPLINE DATA FROM PHASE 1 STUDY EVALUATING THR-687 FOR TREATMENT OF DME

* TOPLINE DATA FROM TRIAL SHOWED THAT THR-687 WAS WELL-TOLERATED AND SAFE WITH NO DOSE-LIMITING TOXICITIES

* NO SERIOUS ADVERSE EVENTS WERE REPORTED AT ANY OF DOSES EVALUATED IN STUDY

* PHASE 2 STUDY WITH THR-687 IN TREATMENT NAÏVE DME PATIENTS TO START IN H2 2020

* OXURION- PHASE 1 STUDY EVALUATED SAFETY OF SINGLE INTRAVITREAL INJECTION OF 3 INCREASING DOSES OF THR FOR DME TREATMENT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below